Hypertensive Disorders in Pregnancy

Introduction

Hypertensive disorders of pregnancy affect approximately 5-10% of all pregnancies worldwide and remain a leading cause of maternal and perinatal morbidity and mortality. These conditions encompass a spectrum of disorders that include chronic hypertension, gestational hypertension, preeclampsia, eclampsia, and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Early recognition, appropriate management, and timely intervention are crucial for optimizing outcomes for both mother and baby.

Blood pressure is considered one of the vital signs monitored throughout pregnancy. A reading of 140/90 mmHg or higher, measured on two separate occasions at least four hours apart, defines hypertension in pregnancy. This article provides comprehensive information about the various hypertensive disorders that can occur during pregnancy, their risk factors, symptoms, management strategies, and long-term implications.

Types of Hypertensive Disorders in Pregnancy

Chronic Hypertension

Chronic hypertension refers to elevated blood pressure that predates pregnancy or is diagnosed before 20 weeks of gestation. It affects approximately 3-5% of pregnancies and is more common in women with certain risk factors, including obesity, advanced maternal age, and preexisting hypertension. Women with chronic hypertension are at increased risk of developing superimposed preeclampsia, fetal growth restriction, placental abruption, and preterm delivery. Careful management before conception and throughout pregnancy is essential for these women.

Gestational Hypertension

Gestational hypertension typically develops after 20 weeks of gestation in women who previously had normal blood pressure. It is characterized by new-onset hypertension without the presence of proteinuria or other features of preeclampsia. While many cases are mild and resolve postpartum, approximately 15-20% progress to preeclampsia. Close monitoring is required to detect signs of progression and ensure maternal and fetal wellbeing.

Preeclampsia

Preeclampsia is a pregnancy-specific syndrome characterized by new-onset hypertension and proteinuria or, in the absence of proteinuria, new hypertension with end-organ dysfunction. It typically occurs after 20 weeks of gestation but can present earlier in women with predisposing conditions such as molar pregnancy or preexisting renal disease. Preeclampsia affects approximately 2-8% of pregnancies and represents a leading cause of maternal and perinatal morbidity worldwide. The pathophysiology involves abnormal placentation, leading to widespread endothelial dysfunction and systemic manifestations affecting multiple organ systems.

Eclampsia

Eclampsia is defined as the occurrence of new-onset seizures in a woman with preeclampsia that cannot be attributed to other causes. It represents the most severe manifestation of the disease and is associated with significant maternal and perinatal morbidity and mortality. The incidence of eclampsia is approximately 1 per 2,000-3,000 deliveries in developed countries but is higher in resource-limited settings. Magnesium sulfate is the drug of choice for prevention and treatment of eclamptic seizures.

HELLP Syndrome

HELLP syndrome is a severe variant of preeclampsia characterized by hemolysis, elevated liver enzymes, and low platelets. It occurs in approximately 0.5-0.9% of all pregnancies and in 10-20% of women with severe preeclampsia. The condition can develop antepartum or postpartum, with most cases occurring between 27 and 37 weeks of gestation. HELLP syndrome is associated with significant maternal complications including disseminated intravascular coagulation, placental abruption, acute renal failure, pulmonary edema, subcapsular liver hematoma, and maternal mortality.

Risk Factors

Several factors increase the risk of developing hypertensive disorders during pregnancy:

• First pregnancy: Nulliparity increases preeclampsia risk.
• Advanced maternal age: Women over 35, and especially over 40, have increased risk.
• Obesity: Pre-pregnancy body mass index (BMI) 30 significantly increases risk.
• Family history: Having a mother or sister who had preeclampsia increases risk.
• Previous preeclampsia: Women who had preeclampsia in a previous pregnancy have higher risk in subsequent pregnancies.
• Multiple gestation: Carrying twins or other multiples increases risk.
• Chronic hypertension: Preexisting hypertension increases risk of superimposed preeclampsia.
• Preexisting diabetes: Both type 1 and type 2 diabetes increase risk.
• Renal disease: Preexisting kidney dysfunction increases risk.
• Autoimmune diseases: Conditions such as systemic lupus erythematosus and antiphospholipid syndrome increase risk.
• Obstetric history: Previous poor pregnancy outcomes (such as fetal growth restriction, stillbirth, or placental abruption) increase risk.
• Thrombophilias: Some inherited conditions that increase clotting risk may also increase preeclampsia risk.

Signs and Symptoms

The signs and symptoms of hypertensive disorders of pregnancy can vary widely, ranging from minimal to severe and life-threatening:

Common Clinical Manifestations

• Elevated blood pressure: Typically 140/90 mmHg or higher.
• Proteinuria: Excess protein in urine (300 mg in 24 hours or protein/creatinine ratio 0.3).
• Headaches: Often severe and persistent, not relieved by usual pain medications.
• Visual disturbances: Blurring, flashing lights, spots, or temporary loss of vision.
• Epigastric or right upper quadrant pain: Due to hepatic involvement.
• Nausea and vomiting: Especially when occurring suddenly in late pregnancy.
• Sudden weight gain: Rapid accumulation of edema, particularly in hands and face.
• Swelling (edema): While mild swelling of ankles is common in pregnancy, sudden or severe swelling requires evaluation.
• Decrease in fetal movements: Potentially indicating fetal compromise.

Signs of Severe Disease

• Blood pressure 160/110 mmHg: On two occasions at least 4 hours apart (or immediately if symptoms present).
• Thrombocytopenia: Platelet count less than 100,000/L.
• Impaired liver function: Elevated liver enzymes to twice normal concentration.
• Renal insufficiency: Serum creatinine greater than 1.1 mg/dL or doubling of baseline.
• Pulmonary edema: Fluid accumulation in lungs.
• New-onset cerebral or visual disturbances: Indicating central nervous system involvement.
• Severe abdominal pain: May indicate hepatic hematoma or impending rupture.

Diagnosis and Screening

Early detection of hypertensive disorders is crucial for optimal management. Screening and diagnostic approaches include:

Routine Blood Pressure Monitoring

Blood pressure should be measured at every prenatal visit using appropriate technique. The patient should be seated quietly for 5 minutes before measurement, with the arm supported at heart level. An appropriately sized cuff should be used, with the bladder encircling at least 80% of the arm. Home blood pressure monitoring can be valuable, especially for women with chronic hypertension or suspected white coat hypertension.

Urine Protein Assessment

Dipstick testing for proteinuria is performed at routine prenatal visits. A single random urine protein:creatinine ratio 0.3 or a 24-hour urine collection containing 300 mg of protein indicates significant proteinuria. In the absence of proteinuria, preeclampsia may still be diagnosed in the presence of other end-organ dysfunction.

Laboratory Evaluation

When hypertensive disorders are suspected or diagnosed, baseline and serial laboratory tests may include:

• Complete blood count with platelets
• Serum creatinine and blood urea nitrogen
• Liver enzymes (AST and ALT)
• Lactate dehydrogenase (as marker of hemolysis)
• Urinalysis
• Coagulation profile (if HELLP syndrome suspected)

Fetal Assessment

Affected pregnancies require careful fetal evaluation including:

• Growth assessment via ultrasound
• Amniotic fluid volume evaluation
• NST (non-stress test) or BPP (biophysical profile) for fetal well-being
• Doppler velocimetry studies of umbilical artery if fetal growth restriction is suspected

Management and Treatment

The management of hypertensive disorders of pregnancy depends on the specific condition, severity, gestational age, and maternal and fetal status. Treatment goals include preventing complications, allowing safe continuation of pregnancy when possible, and optimal timing of delivery.

Blood Pressure Control

Antihypertensive medications are used to prevent severe hypertension in women with preeclampsia and to control blood pressure in women with chronic hypertension. Commonly used medications include:

• Labetalol: A combined alpha- and beta-blocker, often the first-line choice.
• Nifedipine: A calcium channel blocker, particularly useful for acute management.
• Methyldopa: A centrally acting agent with a long safety record in pregnancy.
• Hydralazine: A vasodilator, commonly used for acute severe hypertension.

Seizure Prophylaxis

Magnesium sulfate is the drug of choice for preventing seizures in women with preeclampsia with severe features and for treating eclampsia. It reduces seizure risk by approximately 50% in women with severe preeclampsia. The typical regimen includes a loading dose followed by maintenance infusion, with careful monitoring for signs of magnesium toxicity such as loss of deep tendon reflexes, respiratory depression, and cardiac arrest.

Corticosteroids for Fetal Lung Maturity

Antenatal corticosteroids (betamethasone or dexamethasone) are administered when early delivery is anticipated before 34 weeks of gestation to accelerate fetal lung maturity and reduce complications of prematurity.

Fluid Management

Women with preeclampsia require careful fluid balance management. Many receive restricted maintenance fluids to avoid pulmonary edema. Diuretics are generally avoided except in specific circumstances such as severe pulmonary edema.

Timing of Delivery

The definitive treatment for preeclampsia is delivery of the placenta. The timing depends on gestational age and disease severity:

• Before 34 weeks: Expectant management may be appropriate if maternal and fetal status is stable, with close monitoring.
• 34-36 weeks: Delivery is generally recommended after corticosteroid administration.
• 37 weeks or later: Delivery is recommended for preeclampsia with severe features.

The route of delivery (vaginal vs. cesarean) should be based on obstetric indications, maternal and fetal status, and gestational age, rather than the diagnosis of hypertensive disorder alone.

Postpartum Care

Women with hypertensive disorders of pregnancy require continued monitoring postpartum as preeclampsia can develop or worsen after delivery. Blood pressure should be monitored regularly, and antihypertensive medications should be adjusted as needed. Magnesium sulfate prophylaxis is typically continued for 24 hours after delivery or after the last seizure in women with eclampsia.

Prevention

Several strategies may help reduce the risk of developing hypertensive disorders in pregnancy:

Low-Dose Aspirin

Low-dose aspirin (60-150 mg daily) initiated before 16 weeks of gestation and continued until delivery is recommended for women at high risk of preeclampsia. This intervention can reduce the risk of preeclampsia by approximately 24% in high-risk populations.

Calcium Supplementation

Calcium supplementation (1.5-2.0 g daily) is recommended for women with low dietary calcium intake (<800 mg/day) and may reduce the risk of preeclampsia by up to 50% in this population.

Lifestyle Modifications

• Healthy diet: Balanced nutrition with adequate fruits, vegetables, and whole grains.
• Regular physical activity: Moderate exercise in pregnancy may reduce preeclampsia risk.
• Weight management: Achieving healthy weight before pregnancy and appropriate weight gain during pregnancy.
• Preconception care: Optimizing health before pregnancy, particularly for those with chronic conditions.

Effects on Mother and Baby

Hypertensive disorders of pregnancy can have significant short- and long-term consequences for both mother and baby.

Maternal Outcomes

Acute complications for the mother may include:

• Eclampsia and seizures
• Cerebral hemorrhage
• Placental abruption
• Disseminated intravascular coagulation
• Pulmonary edema
• Acute renal failure
• Hepatic failure or hematoma

Long-term health implications include:

• Increased risk of chronic hypertension
• Elevated risk of cardiovascular disease (stroke, ischemic heart disease)
• Increased risk of renal disease
• Higher likelihood of metabolic syndrome
• Increased risk of recurrent hypertensive disorders in future pregnancies

Fetal and Neonatal Outcomes

Babies born to mothers with hypertensive disorders face risks including:

• Fetal growth restriction
• Hypoxia and acidosis
• Preterm birth
• Low birth weight
• Placental abruption
• Stillbirth
• NICU admission
• Neonatal complications related to prematurity

Conclusion

Hypertensive disorders of pregnancy represent a spectrum of conditions that remain significant contributors to maternal and perinatal morbidity and mortality worldwide. Early recognition through routine prenatal care, appropriate risk stratification, and timely intervention are crucial for optimizing outcomes.

Advances in our understanding of the pathophysiology of these disorders, improved diagnostic capabilities, and evidence-based management guidelines have reduced, but not eliminated, the burden of these conditions. Continued research into preventive strategies, particularly in first-trimester screening and intervention, holds promise for further reducing the impact of these disorders.

Healthcare providers play a critical role in educating women about the signs and symptoms of hypertensive disorders, implementing appropriate screening protocols, and managing affected pregnancies according to evidence-based guidelines. Equally important is the recognition that hypertensive disorders of pregnancy represent not just acute pregnancy complications but may have lasting implications for cardiovascular health, necessitating long-term follow-up and risk reduction strategies.